Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Alterity Therapeutics Ltd ADR (ATHE)

Alterity Therapeutics Ltd ADR (ATHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds Tipranks - Thu Oct 16, 5:38AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Reports Positive ATH434 Phase 2 Trial Results at 2025 MDS Congress Tipranks - Fri Oct 10, 6:08AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alterity...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars Stocktwits - Thu Jan 30, 8:20AM CST

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.

ATHE : 3.10 (+0.16%)
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report PR Newswire - Tue Jan 31, 2023

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire - Fri Jan 6, 2023

/PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum PR Newswire - Tue Jan 3, 2023

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office PR Newswire - Thu Dec 29, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.10 (+0.16%)
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting PR Newswire - Mon Nov 7, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.10 (+0.16%)
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report PR Newswire - Fri Oct 28, 2022

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 3.10 (+0.16%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - Thu Dec 25, 6:30PM CST
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot